Zobrazeno 1 - 10
of 4 826
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
BMC cancer, 22(1):130
BMC Cancer
BMC cancer, 22(1):130
BMC Cancer
BackgroundWe aimed to explore the potential of German claims data for describing initial and long-term treatment patterns of breast cancer patients undergoing surgery.MethodsUsing the German Pharmacoepidemiological Research Database (GePaRD, ~ 20% of
Autor:
Courtney Andrews, Timothy C. Childers, Kimberly D. Wiseman, Valerie Lawhon, Stacey Ingram, Mary Lou Smith, Antonio C. Wolff, Lynne Wagner, Gabrielle B. Rocque
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background As the combination of systemic and targeted chemotherapies is associated with severe adverse side effects and long-term health complications, there is interest in reducing treatment intensity for patients with early-stage breast cancer (EB
Autor:
Tomoko Yoshida, Kazuhiko Takeda, Toshihiko Kaneda, Hiroaki Yanagimoto, Takao Yoshida, Kayoko Kibata, Koji Tsuta, Takayasu Kurata, Hiroshige Yoshioka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy
Autor:
Lydia, Guittet, Valérie, Quipourt, Thomas, Aparicio, Elisabeth, Carola, Jean-François, Seitz, Elena, Paillaud, Astrid, Lievre, Rabia, Boulahssass, Carole, Vitellius, Leila, Bengrine, Florence, Canoui-Poitrine, Sylvain, Manfredi
Publikováno v:
BMC Cancer
BMC Cancer, 2023, 23 (1), pp.17. ⟨10.1186/s12885-022-10418-5⟩
BMC Cancer, 2023, 23 (1), pp.17. ⟨10.1186/s12885-022-10418-5⟩
Background We have done a systematic literature review about CRC Screening over 75 years old in order to update knowledge and make recommendations. Methods PUBMED database was searched in October 2021 for articles published on CRC screening in the el
Publikováno v:
BMC Cancer. 22
Background Cancer is a major public health problem with pharmacotherapy being the cornerstone of its management. Cancer patients receive multiple drugs concurrently risking Drug-Drug Interactions (DDIs). DDIs, though avoidable, can significantly cont
Autor:
Joseph, Kattan, Fady El, Karak, Fadi, Farhat, Dany Abi, Gerges, Walid, Mokaddem, Georges, Chahine, Saad, Khairallah, Najla, Fakhruddin, Jawad, Makarem, Fadi, Nasr
Publikováno v:
BMC Cancer
BMC Cancer, 2022, 22 (1), pp.1114. ⟨10.1186/s12885-022-10206-1⟩
BMC Cancer, 2022, 22 (1), pp.1114. ⟨10.1186/s12885-022-10206-1⟩
Background This study aimed to report the prevalence of HER2-neu in newly diagnosed early or metastatic gastric cancer (GC) patients, to determine the percentage of patients achieving various IHC scores correlating with the ISH results and to establi
Autor:
Astrid Louise Bjørn Bennedsen, Luyi Cai, Rune Petring Hasselager, Aysun Avci Özcan, Khadra Bashir Mohamed, Jens Ole Eriksen, Susanne Eiholm, Michael Bzorek, Anne-Marie Kanstrup Fiehn, Thomas Vauvert F. Hviid, Ismail Gögenur
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-19 (2022)
Bennedsen, A L B, Cai, L, Hasselager, R P, Özcan, A A, Mohamed, K B, Eriksen, J O, Eiholm, S, Bzorek, M, Fiehn, A-M K, Hviid, T V F & Gögenur, I 2022, ' An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer ', BMC Cancer, vol. 22, 62 . https://doi.org/10.1186/s12885-022-09169-0
BMC Cancer
Bennedsen, A L B, Cai, L, Hasselager, R P, Özcan, A A, Mohamed, K B, Eriksen, J O, Eiholm, S, Bzorek, M, Fiehn, A-M K, Hviid, T V F & Gögenur, I 2022, ' An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer ', BMC Cancer, vol. 22, 62 . https://doi.org/10.1186/s12885-022-09169-0
BMC Cancer
Background The immune system recognizes and destroys cancer cells. However, cancer cells develop mechanisms to avoid detection by expressing cell surface proteins. Specific tumour cell surface proteins (e.g. HLA-G, PD-L1, CDX2) either alone or in com
Autor:
Benyamin Hoseini, Zahra Rahmatinejad, Ladan Goshayeshi, Robert Bergquist, Amin Golabpour, Kamran Ghaffarzadegan, Fatemeh Rahmatinejad, Reza Darrudi, Saeid Eslami
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background The incidence rate of colorectal cancer (CRC) is increasing among patients below 50 years of age. The reason for this is unclear, but could have to do with the fact that indicative variables, such as tumour location, gender preference and
Autor:
Stephanie Tuminello, Naomi Alpert, Rajwanth R. Veluswamy, Arvind Kumar, Jorge E. Gomez, Raja Flores, Emanuela Taioli
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
BMC Cancer
BMC Cancer
Background It has been postulated that patient’s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit, however, has not yet been explored using patient-level data, where potential confounders, as well as histologic type, c
Autor:
San-Chi Chen, Yi-Hsiang Huang, Ming-Huang Chen, Yi-Ping Hung, Rheun-Chuan Lee, Yu-Yun Shao, Yee Chao
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
BMC Cancer
BMC Cancer
Background Vascular endothelial growth factor (VEGF) plays a role in the tumor microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation function but lacks substantial clinical data. This study aims to explore the efficac